American Century Companies’s Beam Therapeutics BEAM Stock Holding History

American Century Companies’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.03M	Buy	204,697 +36,024	+21%	+$1.09M	﹤0.01%	1735
2026 Q1	$4.02M	Buy	168,673 +20,370	+14%	+$565K	﹤0.01%	1869
2025 Q4	$4.11M	Buy	148,303 +98,110	+195%	+$2.5M	﹤0.01%	1816
2025 Q3	$1.22M	Buy	50,193 +36,534	+267%	+$727K	﹤0.01%	2236
2025 Q2	$232K	Sell	13,659 -85,902	-86%	-$1.5M	﹤0.01%	2712
2025 Q1	$1.94M	Sell	99,561 -35,819	-26%	-$938K	﹤0.01%	1993
2024 Q4	$3.36M	Buy	135,380 +15,774	+13%	+$403K	﹤0.01%	1777
2024 Q3	$2.93M	Buy	119,606 +24,028	+25%	+$621K	﹤0.01%	1802
2024 Q2	$2.24M	Buy	95,578 +23,837	+33%	+$585K	﹤0.01%	1864
2024 Q1	$2.37M	Buy	71,741 +14,740	+26%	+$459K	﹤0.01%	1812
2023 Q4	$1.55M	Buy	57,001 +22,231	+64%	+$552K	﹤0.01%	1895
2023 Q3	$836K	Buy	+34,770	New	+$932K	﹤0.01%	2059
2021 Q4	–	Sell	-8,102	Closed	-$705K	–	2318
2021 Q3	$705K	Buy	+8,102	New	+$814K	﹤0.01%	1745

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

American Century Companies's BEAM Position: Q2 2026 in Review

American Century Companies increased its Beam Therapeutics (BEAM) stake by 21% in Q2 2026, buying an estimated $1.09M and bringing the position to 204,697 shares worth $7.03M. The position accounts for ﹤0.01% of the portfolio, ranked #1735.

American Century Companies first reported a position in BEAM in Q3 2021 and has held it in 13 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

American Century Companies held 204,697 shares of Beam Therapeutics worth $7.03M as of Q2 2026.
American Century Companies bought 36,024 Beam Therapeutics shares in Q2 2026, an estimated $1.09M.
Beam Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #1735 holding.
American Century Companies first reported a position in Beam Therapeutics in Q3 2021 and has held it in 13 quarters since.
277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.